Evidence map›Paper›PMID 36952634›Full record

Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2023

Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer.

Kim N Chi, Dana Rathkopf, Matthew R Smith, Eleni Efstathiou, Gerhardt Attard, David Olmos, Ji Youl Lee, Eric J Small, Andrea J Pereira de Santana Gomes, Guilhem Roubaud and 11 more

2 registry-linked trialsOpen access · hybridAbstract readRandomized Controlled TrialClinical Trial, Phase III
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 199 papers, 15 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
199citing papers in PubMed, 15 pooled it
77.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03748641 phase3active not recruitingnot on this map

A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Metastatic Prostate Cancer

TypeinterventionalSponsorJanssen Research & Development, LLCRan2019 to 2027Enrolled765ConditionsCastration-Resistant Prostatic CancerArmsNiraparib, Abiraterone Acetate, Prednisone, Placebo, New Formulation of Niraparib and Abiraterone Acetate (AA)
NCT06329830 phase1 / phase2withdrawnnot on this mapstarted 2024, after this paper: background citation

Safety and Anti-tumor Activity of Lutetium-177 (177Lu)-PSMA-617 Along With Niraparib and Abiraterone Acetate Plus Prednisone in Metastatic Castration Resistant Prostate Cancer - LUNAAR Study

TypeinterventionalSponsorBaptist Health South FloridaRan2024 to 2028Enrolled0ConditionsMetastatic Prostate Cancer, Castration-resistant Prostate Cancer, Metastatic Castration-resistant Prostate CancerArms177Lu-PSMA-617, Niraparib abiraterone acetate, Prednisone
3 · Its place in the literature

Who cites it

199 citing papers in PubMed, 15 syntheses or guidelines pooled it, 299 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Guideline
  7. Pooled it
  8. Recommendations from the Galician Oncological Society and the Galician Society of Nuclear Medicine for the use ofClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Guideline
  9. Pooled it
  10. Pooled it
  11. Comparative effectiveness of first-line systemic treatments for metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024
    Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

139 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 13 institutions in 9 countries.

Kim N ChiBC Cancer - Vancouver Center, University of British Columbia, Vancouver, BC, Canada.ORCID 0000-0002-3782-7226
Dana RathkopfMemorial Sloan Kettering Cancer Center and Weill Cornell Medicine, New York, NY.
Matthew R SmithMassachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA.
Eleni EfstathiouHouston Methodist Cancer Center, Houston, TX.ORCID 0000-0002-3868-1396
Gerhardt AttardUniversity College London, London, UK.ORCID 0000-0002-4811-7983
David OlmosDepartment of Medical Oncology, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain.ORCID 0000-0002-7003-4826
Ji Youl LeeDepartment of Urology Cancer Center, Seoul St Mary's Hospital, The Catholic University of Korea, Seoul, South Korea.ORCID 0000-0001-6775-1157
Eric J SmallHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA.ORCID 0000-0003-3191-6268
Andrea J Pereira de Santana GomesLiga Norte Riograndense Contra o Câncer, Natal, Brazil.ORCID 0000-0001-7388-663X
Guilhem RoubaudDepartment of Medical Oncology, Institut Bergonié, Bordeaux, France.
Marniza SaadDepartment of Clinical Oncology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Bogdan ZurawskiDepartment of Outpatient Chemotherapy, Professor Franciszek Lukaszczyk Oncology Center, Bydgoszcz, Poland.
Valerii SakaloKyiv City Clinical Oncology Center and Academician O.F. Vozianov Institute of Urology of the National Academy of Medical Sciences of Ukraine, Kyiv, Ukraine.
Gary E MasonJanssen Research & Development, LLC, Spring House, PA.ORCID 0000-0002-3023-687X
Peter FrancisJanssen Research & Development, LLC, Raritan, NJ.
George WangJanssen Research & Development, LLC, Spring House, PA.
Daphne WuJanssen Research & Development, LLC, Los Angeles, CA.
Brooke DiorioJanssen Research & Development, LLC, Titusville, NJ.
Angela Lopez-GitlitzJanssen Research & Development, LLC, Los Angeles, CA.
Shahneen SandhuPeter MacCallum Cancer Centre and the University of Melbourne, Melbourne, Australia.ORCID 0000-0002-8660-4475
MAGNITUDE Principal Investigators
Janssen (United States) · USHarvard University · USInstitut Bergonié · FRState Institution «Academician O.F.Vozianov Institute of Urology of the National Academy of Medical Sciences of Ukraine» · UAThe Catholic University of Korea Seoul St. Mary's Hospital · KRThe University of Melbourne · AUUniversity College London · GBUniversity of Malaya · MYHospital Universitario 12 De Octubre · ESHouston Methodist · USMemorial Sloan Kettering Cancer Center · USUniversity of British Columbia · CAUniversity of California, San Francisco · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

purposeMetastatic castration-resistant prostate cancer (mCRPC) remains a lethal disease with current standard-of-care therapies. Homologous recombination repair (HRR) gene alterations, including

methodsMAGNITUDE (ClinicalTrials.gov identifier: NCT03748641) is a phase III, randomized, double-blinded study that evaluates niraparib and abiraterone acetate plus prednisone (niraparib + AAP) in patients with (HRR+, n = 423) or without (HRR-, n = 247) HRR-associated gene alterations, as prospectively determined by tissue/plasma-based assays. Patients were assigned 1:1 to receive niraparib + AAP or placebo + AAP. The primary end point, radiographic progression-free survival (rPFS) assessed by central review, was evaluated first in the

resultsMedian rPFS in the

conclusionCombination treatment with niraparib + AAP significantly lengthened rPFS in patients with HRR+ mCRPC compared with standard-of-care AAP. [Media: see text].

Indexed as

Abiraterone AcetateProstatic Neoplasms, Castration-ResistantAntineoplastic Combined Chemotherapy ProtocolsBRCA1 ProteinBRCA2 ProteinHumansIndazolesMalePiperidinesPrednisoneAbiraterone AcetateBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanIndazolesniraparibPiperidinesPrednisone

Identifiers

PMID36952634
PMCPMC10431499
OpenAlexW4360608257

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.